文献速递炎症性肠病

晚发型中重度溃疡性结肠炎住院患者静脉激素治疗有效性较低:一项多中心队列研究

Lower effectiveness of intravenous steroid treatment for moderate-to-severe ulcerative colitis in hospitalised patients with older onset: a multicentre cohort study.
PubMed 文献 · Aliment Pharmacol Ther · 2022-03-11

这项回顾性多中心队列研究纳入467例中重度住院溃疡性结肠炎患者,比较晚发型与早发型患者首次静脉激素治疗的效果。晚发型患者第30天临床缓解率较低(51.8% vs 65.6%),90天内手术风险及不良事件风险均更高,4例死亡均发生于晚发型患者。

要点

  • 晚发型患者第30天临床缓解率51.8%,低于早发型65.6%,校正风险比0.74。
  • 晚发型患者90天内手术风险20.5%,高于早发型3.1%,校正风险比8.92。
  • 晚发型患者90天内不良事件风险25.3%,高于早发型9.1%,校正风险比2.19。

核心结论

  • 晚发型与静脉激素有效性较低相关,且手术及不良事件风险更高。

研究设计与样本

  • 回顾性多中心(27家机构)队列研究,纳入2014年4月至2019年7月间首次接受静脉激素治疗的中重度住院溃疡性结肠炎患者467例(早发型384例,晚发型83例)。
  • 主要结局为第30天临床缓解(采用两项患者报告结局评分),关键次要结局为90天内手术及不良事件(死亡、感染、静脉血栓)风险,采用改良Poisson回归模型分析。

主要发现

  • 第30天临床缓解:晚发型43例(51.8%)vs 早发型252例(65.6%),校正风险差-21.7%(95%CI -36.1%至-7.2%),校正风险比0.74(95%CI 0.59至0.93)。
  • 90天内手术风险:晚发型20.5% vs 早发型3.1%,校正风险比8.92(95%CI 4.13至19.27)。
  • 90天内不良事件风险:晚发型25.3% vs 早发型9.1%,校正风险比2.19(95%CI 1.22至3.92)。
  • 感染风险:晚发型18.1% vs 早发型8.6%;静脉血栓风险:晚发型7.2% vs 早发型0.5%。
  • 共发生4例死亡,均涉及晚发型溃疡性结肠炎。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The increasing incidence of older-onset ulcerative colitis (UC), which has a higher risk of surgery, is a global health issue. However, data regarding intravenous steroid treatment, one of the important treatment options to avoid surgery, for older-onset UC is lacking. AIMS: To evaluate the association between onset age and effectiveness of intravenous steroids in UC. METHODS: This retrospective multicentre (27 facilities) cohort study included moderate-to-severe hospitalised UC patients who underwent their first intravenous steroids between April 2014 and July 2019. The primary outcome was clinical remission at day 30, using two-item patient-reported outcome scoring. The key secondary outcomes were risks of surgery and adverse events (death, infection and venous thrombosis) within 90 days. A modified Poisson regression model was used for analysis. RESULTS: Overall, 467 UC patients (384 younger-onset and 83 older-onset) were enrolled. Clinical remission at day 30 was observed in 252 (65.6%) among younger-onset patients and 43 (51.8%) among older-onset patients (adjusted risk difference, -21.7% [95% CI, -36.1% to -7.2%]; adjusted risk ratio [ARR], 0.74 [95% CI, 0.59 to 0.93]). The risks of surgery and adverse events were higher in older-onset UC (20.5% vs. 3.1%; ARR, 8.92 [95% CI, 4.13 to 19.27], 25.3% vs. 9.1%; ARR, 2.19 [95% CI, 1.22 to 3.92], respectively). Four deaths occurred, all involving older-onset UC. The risks of infection and venous thrombosis were also higher in older-onset UC (18.1% vs. 8.6%, 7.2% vs. 0.5%, respectively). CONCLUSIONS: Older-onset was associated with a lower effectiveness of intravenous steroids with higher risks of surgery and adverse events in UC.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Okabayashi S, Yamazaki H, Tominaga K, et al. Lower effectiveness of intravenous steroid treatment for moderate-to-severe ulcerative colitis in hospitalised patients with older onset: a multicentre cohort study. Aliment Pharmacol Ther. 2022. PMID: 35274323. doi:10.1111/apt.16865

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。